Anticancer drug bexarotene inhibits build-up of toxic Alzheimer’s protein
Bexarotene, a drug approved by the U.S. Food and Drug Administration to treat skin cancer, stopped the primary nucleation step in the self-assembly of amyloid-beta-42 oligomers and delayed the...
Source: Clinical Neurology News - Category: Neurology Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Neurology | Skin | Skin Cancer | Toxicology